-brenztraubensaeure-ethylester | 103204-67-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: -brenztraubensaeure-ethylester
• 英文别名: 2-oxo-3-pyridin-4-yl-propionic acid ethyl ester；Ethyl 2-oxo-3-(pyridin-4-yl)propanoate；ethyl 2-oxo-3-pyridin-4-ylpropanoate
• CAS: 103204-67-7
• 化学式: C₁₀H₁₁NO₃
• mdl: MFCD11858126
• 分子量: 193.202
• InChiKey: HQQNCGGAZBRDJB-UHFFFAOYSA-N

物化性质

• 沸点：
  324.2±25.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-甲基吡啶 、 草酸二乙酯 在 potassium tert-butylate 作用下， 以 乙醚 为溶剂， 以38%的产率得到-brenztraubensaeure-ethylester
  参考文献：
  名称：

  烷基杂芳基丙酮酸盐的简便合成

  摘要：

  摘要 在叔丁醇钾存在下，将相应的甲基取代的吖嗪或唑类与草酸二乙酯缩合得到几种乙基杂芳基丙酮酸酯。所得化合物仅或主要以烯醇形式存在。

  DOI：

  10.1080/00397919208019078

文献信息

• [EN] INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA<br/>[FR] INHIBITION DE LA PHOSPHOINOSITIDE 3-KINASE BETA
  申请人：KINACIA PTY LTD

  公开号：WO2004016607A1

  公开（公告）日：2004-02-26

  The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase ß, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase ß of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

  本发明涉及磷酸肌醇（PI）3-激酶β的选择性抑制剂，以及这些选择性抑制剂在抗血栓治疗中的应用，以及通过检测化合物对PI 3-激酶β的选择性抑制活性来筛选对新型抗血栓治疗有用的化合物的方法。该发明还涉及作为PI 3-激酶抑制剂的新化合物。
• Inhibition Of Phosphoinositide 3-Kinase Beta
  申请人：Jackson Shaun P.

  公开号：US20080319021A1

  公开（公告）日：2008-12-25

  The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

  本发明涉及选择性磷脂酰肌醇（PI）3-激酶β的抑制剂，使用这些选择性抑制剂进行抗血栓治疗的方法，以及通过检测化合物的PI 3-激酶β的选择性抑制活性筛选有用于新抗血栓治疗的化合物的方法。该发明还涉及新型PI 3-激酶抑制剂化合物。
• Inhibition of phsphoinostide 3-dinase beta
  申请人：Jackson P. Shaun

  公开号：US20060276470A1

  公开（公告）日：2006-12-07

  The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

  本发明涉及选择性抑制磷脂酰肌醇（PI）3-激酶β的抑制剂，使用这些选择性抑制剂进行抗血栓治疗的方法，以及通过检测化合物的PI 3-激酶β的选择性抑制活性筛选有用于新的抗血栓治疗的化合物的方法。本发明还涉及新的PI 3-激酶抑制剂化合物。
• SYNTHESIS METHOD FOR L-HETEROCYCLIC AMINO ACID AND PHARMACEUTICAL COMPOSITION HAVING THEREOF
  申请人：ASYMCHEM LABORATORIES (TIANJIN) CO., LTD

  公开号：US20160153015A1

  公开（公告）日：2016-06-02

  A synthesis method for an L-heterocyclic amino acid and a pharmaceutical composition having the said amino acid are provided in the present disclosure. The synthesis method comprises: step A: preparing a heterocyclic keto acid, wherein the heterocycle in the heterocyclic keto acid is selected from any one of a five-membered heterocycle, a six-membered heterocycle, a seven-membered heterocycle, an alkyl-substituted five-membered heterocycle, an alkyl-substituted six-membered heterocycle, and an alkyl-substituted seven-membered heterocycle, and the keto acid group in the heterocyclic keto acid has a structural formula of and is located on any one of the carbon positions of the heterocycle, and step B: mixing the heterocyclic keto acid with ammonium formate, a phenylalanine dehydrogenase, a formate dehydrogenase and a coenzyme NAD + , and carrying out a reductive amination reaction to generate L-heterocyclic amino acid, wherein the amino acid sequence of the phenylalanine dehydrogenase is SEQ ID No. 1.

  本公开提供了一种L-杂环氨基酸的合成方法和具有该氨基酸的制药组合物。该合成方法包括：步骤A：制备杂环酮酸，其中杂环在杂环酮酸中选自五元杂环、六元杂环、七元杂环、烷基取代的五元杂环、烷基取代的六元杂环和烷基取代的七元杂环，而杂环酮酸中的酮酸基具有结构式，位于杂环的任一碳位上；步骤B：将杂环酮酸与甲酸铵、苯丙氨酸脱氢酶、甲酸脱氢酶和辅酶NAD+混合，并进行还原胺化反应以生成L-杂环氨基酸，其中苯丙氨酸脱氢酶的氨基酸序列为SEQ ID No. 1。
• INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA
  申请人：Kinacia Pty Ltd.

  公开号：EP1537102A1

  公开（公告）日：2005-06-08